Casdin Capital, LLC
Casdin Capital, LLC reported 48 holdings worth US$2.3B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Casdin Capital, LLC reported 48 holdings worth US$2.3B as of Sep 30, 2026. Largest: Revolution Medicines, Inc., Relay Therapeutics, Inc. and GeneDx Holdings Corp. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 48
- Value as reported
- US$2.3B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Revolution Medicines, Inc. | 2.58M | US$529M | 23.0% |
| Relay Therapeutics, Inc. | 16M | US$289M | 12.6% |
| GeneDx Holdings Corp. | 3.71M | US$268M | 11.7% |
| BioLife Solutions, Inc. | 4.5M | US$175M | 7.6% |
| Illumina, Inc. | 530K | US$145M | 6.3% |
| GRAIL, Inc. | 680K | US$95.3M | 4.2% |
| 10x Genomics, Inc. | 1.05M | US$94.9M | 4.1% |
| Standard BioTools Inc. | 88.8M | US$65.8M | 2.9% |
| Neurogene Inc. | 1.59M | US$44.1M | 1.9% |
| Scholar Rock Holding Corporation | 850K | US$41.1M | 1.8% |
| Personalis, Inc. | 2.3M | US$37.4M | 1.6% |
| Beam Therapeutics Inc. | 1.5M | US$36.7M | 1.6% |
| Tempus AI, Inc. | 424K | US$34.7M | 1.5% |
| Sarepta Therapeutics, Inc. | 1.82M | US$33.2M | 1.4% |
| Guardant Health, Inc. | 185K | US$33M | 1.4% |
| Structure Therapeutics, Inc. | 1.03M | US$32.2M | 1.4% |
| Alnylam Pharmaceuticals, Inc. | 120K | US$29.6M | 1.3% |
| Denali Therapeutics Inc. | 1.25M | US$25.8M | 1.1% |
| Hims & Hers Health, Inc. | 800K | US$23.8M | 1.0% |
| Maze Therapeutics, Inc. | 844K | US$22.9M | 1.00% |
| Septerna, Inc. | 553K | US$21.6M | 0.94% |
| Parabilis Medicines, Inc. | 646K | US$20.8M | 0.91% |
| Adlai Nortye Group Ltd. | 1.25M | US$20M | 0.87% |
| Taysha Gene Therapies, Inc. | 3.9M | US$19M | 0.83% |
| AgomAb Therapeutics NV | 1.55M | US$17.2M | 0.75% |
| ORIC Pharmaceuticals, Inc. | 1.25M | US$16.8M | 0.73% |
| Moderna, Inc. | 75,000 | US$14.4M | 0.63% |
| Veracyte, Inc. | 276K | US$12.7M | 0.55% |
| Quest Diagnostics Incorporated | 50,000 | US$11.7M | 0.51% |
| Biogen Inc. | 50,000 | US$11.3M | 0.49% |
| Edgewise Therapeutics, Inc. | 265K | US$10.8M | 0.47% |
| Absci Corporation | 973K | US$10.5M | 0.46% |
| Prime Medicine, Inc. | 3.17M | US$9.68M | 0.42% |
| BioNTech SE | 85,000 | US$8.36M | 0.36% |
| Braveheart Bio, Inc. | 400K | US$8.08M | 0.35% |
| Rapport Therapeutics, Inc. | 200K | US$6.72M | 0.29% |
| Intellia Therapeutics, Inc. | 355K | US$4.28M | 0.19% |
| Century Therapeutics, Inc. | 1.23M | US$2.1M | 0.09% |
| Contineum Therapeutics, Inc. | 148K | US$1.99M | 0.09% |
| Pacific Biosciences of California, Inc. | 724K | US$1.72M | 0.07% |
| BridgeBio Oncology Therapeutics, Inc. | 282K | US$1.16M | 0.05% |
| Editas Medicine, Inc. | 445K | US$1.14M | 0.05% |
| Monte Rosa Therapeutics, Inc. | 86,014 | US$1.03M | 0.04% |
| Kardigan, Inc. | 50,000 | US$738K | 0.03% |
| Recursion Pharmaceuticals, Inc. | 165K | US$683K | 0.03% |
| Ginkgo Bioworks Holdings, Inc. | 36,493 | US$468K | 0.02% |
| Tenaya Therapeutics, Inc. | 362K | US$218K | <0.01% |
| Disc Medicine, Inc. | 0 | US$0 | 0.00% |
| Sionna Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related